

Title:

“There’s a big tag on my head”: exploring barriers to treatment seeking with women who use methamphetamine in Sydney, Australia

Authors:

*Brendan Clifford^{1,2,3,4}, Kate Van Gordon^{1,5}, Fiona Magee⁶, Victoria Malone¹, Krista Siefried^{1,2,3} Duncan Graham^{2,3}, Nadine Ezard^{1,2,3,7}

1 Alcohol & Drug Service, St Vincent’s Hospital Sydney, New South Wales, Australia

2 National Centre for Clinical Research on Emerging Drugs of Concern, Sydney, New South Wales, Australia

3 National Drug and Alcohol Research Centre, University of New South Wales Sydney, Australia

4 Susan Wakil School of Nursing & Midwifery, University of Sydney, New South Wales, Australia

5 Victor Medical Centre, Victor Harbor, South Australia, Australia

6 South Eastern Sydney Local Health District, New South Wales, Australia

7 Drug and Alcohol Clinical Research and Improvement Network, Sydney, New South Wales, Australia

*Corresponding author

Email: brendan.clifford@svha.org.au

Postal Address: St Vincent’s Hospital, Darlinghurst, New South Wales, Australia 2010

Abstract

Background

Australia has a high prevalence of regular use of methamphetamine (MA). While half of people who use MA regularly are women, they make up only one third of people seeking treatment for MA use disorder (MaUD). There is a lack of qualitative research into the facilitators and barriers to treatment for women who use MA regularly. The study seeks a better understanding of the experiences and treatment preferences of women who use MA, to inform person-centred changes in practice and policy that break down barriers to treatment.

Methods

We conducted semi-structured interviews with 11 women who frequently use MA (at least once a week), and who are not engaged in treatment. Women were recruited from health services surrounding a stimulant treatment centre at an inner-city hospital. Participants were asked about their MA use and health service needs and preferences. Thematic analysis was completed using Nvivo® software.

Results

Three themes were developed from participants' responses around experiences of regular MA use and treatment needs: 1. Resistance of stigmatised identity including dependence; 2. Interpersonal violence; 3. Institutionalised stigma. Clear service delivery preferences were

46 also elicited, including continuity of care, integrated health care, and provision of non-
47 judgmental services.

48 **Conclusion**

49 Gender-inclusive health care services for people who use MA should actively work to
50 address stigma, support a relational approach to assessment and treatment, and seek to
51 provide structurally competent health care that is trauma and violence informed, and
52 integrated with other services. Findings may also have application for substance use
53 disorders other MA.

54

55 Key words (3-10)

56 Methamphetamine, methamphetamine use disorder, gender, health services accessibility

57

58

59

60

61

Background

The use of MA is a growing public health concern globally (Farrell et al., 2019), with MA related death rates increasing in Australia from 0.14 to 0.44 per 100,000 population between 2012 and 2016 (Man et al., 2022). Harms associated with MA use include depression, anxiety, psychosis, cardiovascular disease, cerebrovascular disease (Chomchai & Chomchai, 2015), and the development of MaUD (Degenhardt et al., 2017). Evidence-based therapies for MaUD include psychosocial interventions such as Cognitive Behavioural Therapy (CBT) (Asharani et al., 2020) with ongoing work to develop adjunct pharmacotherapies (Siefried, Acheson, Lintzeris, & Ezard, 2020). In Australia, despite high rates of regular use of MA and MaUD, there is relatively low treatment utilisation, with a gap of five (Lee, Harney, & Pennay, 2012) to ten years (Brecht, Lovinger, Herbeck, & Urada, 2013) between first problematic use of MA and the seeking of treatment. This is partly due to self-perceived non-problematic use, even after people have begun to experience harms associated with MA (Quinn, Stooze, Papanastasiou, & Dietze, 2013). People who use MA, however, also report low confidence in the efficacy of treatment services and cite the opiate-centric nature of alcohol and other drug (AOD) services as barriers to help-seeking (Cumming, Troeung, Young, Kelty, & Preen, 2016; Kenny, Harney, Lee, & Pennay, 2011; Rapp et al., 2006). Specialist treatment services that provide psychological and medical interventions for people experiencing MaUD delivered within a non-judgmental, harm reduction framework have been found to be attractive to participants (Brenner et al., 2018) and effective in providing significant reductions in MA use and associated harms (McKetin et al., 2013).

Substance use remains deeply gendered in Australia, being seen as of rite of passage and a form of active exploration in masculinity, but linked with “ineffective coping mechanisms” (Frydenberg, 2014) and a need to quell internal psychological struggles when associated with femininity (Keane, 2017). Importantly, evidence suggests that once in treatment for MaUD, outcomes for women may be better than those for men. In a longitudinal Californian study of people in treatment, for instance, women demonstrated greater improvement in family relationships and medical problems compared to men. This was despite women in the sample being more likely than men to be unemployed, have childcare responsibilities, live with someone who also used substances, have been physically or sexually abused, and to have more psychiatric symptoms (Hser, Evans, & Huang, 2005). In Australia, however, women are less likely to participate in treatment (McKetin & Kelly, 2007), making up only a third of people who access treatment for MaUD (Australian Institute of Health and Welfare, 2020), despite being as likely as men to use MA weekly (Roche, McEntee, Fischer, & Kostadinov, 2015).

This study was undertaken to understand the nature of barriers to specialist MaUD treatment for women in metropolitan area of Sydney, Australia. Rather a fixed binary epidemiological or clinical category, it understands gender as complex social phenomenon that extends beyond these classifications (Martin & Aston, 2014), and seeks to build the voices of women into contemporary clinical practice.

Methods

Design

An exploratory qualitative methodology was used to assess experiences of women who regularly MA but who have not accessed a specialised MA treatment service. The study setting was an inner-city tertiary Australian hospital with a free specialist treatment program for people with that provides assessment and early intervention (Brener et al., 2018) and outpatient counselling (McKetin et al., 2013). Ethics approval was obtained from St Vincent's Hospital Human Research Ethics Committee (LNR/15/SVH/469).

Sampling and data collection

Study advertisements were placed in local and community health centres, drug and alcohol services, and women's refuges seeking interviews with people who identified as women and who used MA at least weekly, were not engaged in MA specific treatment, and were aged at least 18 years. Prospective participants were asked to contact the investigator team by telephone to arrange an interview time, where informed consent was obtained. Participants were given an AU\$20 grocery voucher prior to completing demographic and substance use questionnaires, the Severity of Dependence Scale (SDS) (Gossop et al., 1995) and undertaking a semi-structured interview exploring participants experiences of methamphetamine use, health care services and treatment preferences for MaUD.

Analysis

The interview data are recognised as being co-created by participant and interviewer, and both the data and its analysis influenced by the perspectives and genders of the researchers (Broom, Hand, & Tovey, 2009). The interviews were transcribed, and analysed thematically (Braun & Clarke, 2006). Authors KVG, FM, BC and VM initially coded two transcripts each using NVivo® (QSR International) software examining participants' relationship to and experiences of MA use; barriers experienced in access to care; use of health services; and perceived treatment needs. The study team then met to examine emergent subthemes from the codes, exploring linkages between themes and subthemes, searching for negative or deviant examples, extracting quotes to exemplify arguments, and developed a thematic framework with which to analyse the remaining transcripts. After the remaining transcripts were coded, the team met again to re-evaluate the validity of the themes and draw out meta-themes.

Results

A total of eleven women who used methamphetamine were interviewed, mainly recruited from non-gender specific AOD services. Participant characteristics are presented in **Table 1**. Four themes were developed from the data: identity, stigma and resistance; interpersonal violence; institutionalised stigma; and service delivery preferences. Quotes are provided to illustrate each theme, with the participant identification number, age range and SDS score also provided for context.

Identity, stigma and resistance

Several participants emphasised the positive aspects of their MA use, such as how it enabled productivity, or as a form of recreation.

“My first experience ... I found that it elevated my levels of perception and my levels of superwoman likeness ... in a way that I could achieve many things in a short period of time.”

(Participant 3, age 31-35, SDS 1)

Nonetheless, stigmatising language was used by the participants themselves in describing MA use.

“The methamphetamine scene - I have never seen such putrid behaviour. I've never seen such vile creatures or predators or soulless people in my life and it has been truly a very disheartening experience.” (Participant 3, age 31-35, SDS 1)

They also described the stigma they felt in being identifiable as someone who used drugs.

“I sort of feel like there's a big tag on my head that says I'm a drug user (laughs). I don't know but I just stand out.” (Participant 1, age >50, SDS 5)

This affected their sense of belonging and identity within their families.

“My family judged me. They judged my loss of weight, they judged my appearance, they judged the fact that I had lost everything in my life” (Participant 3, age 31-35, SDS 1)

178 The loss of custody of children in relation to their MA use and implications of this on their
179 sense of self, was also discussed by participants.

180

181 *"It's not pleasant. I really need to go back to family. There are things that the ice has stopped*
182 *me from doing like things that I should be doing."* (Participant 6, age 41-45, SDS 9)

183

184 *"No one ever gave me a pat on the back to say, you know " Good, we recognise that you've*
185 *made major changes because of your children" ...you know I don't want to be labelled like a*
186 *bad parent."* (Participant 1, age >50, SDS 5)

187

188 Participants characterised their own use as being different to problematic or dependent
189 use.

190

191 *"I certainly wouldn't say that I am addicted to it...It takes a very strong personality to take a*
192 *drug for three days and then stop because this drug is by far the most addictive drug out of*
193 *all of them."* (Participant 3, age 31-35, SDS 1)

194

195 Participants also highlighted the difference between their use with the use of others, both
196 in terms of "controlled use" and better management of the consequences of use.

197

198 *"I feel sorry for her...she doesn't have that self-control that's just the mind over matter*
199 *thing."* (Participant 3, age 31-35, SDS 1)

200

201 *"Ah it's just disgusting...she must probably shoot up her neck, so wherever the shooting site*
 202 *is...If I even see a couple of spots on me, I'm straight to the doctor. I don't wanna turn out*
 203 *like that."* (Participant 1, age >50, SDS 5)

204

205 Interpersonal violence

206

207 Several participants spoke of their intimate partner relationships as being innately linked
 208 with their use of MA. These relationships were also associated with the experience of
 209 violence.

210

211 *"It was in a domestic violent relationship and the deal with him was if I were to use it, I had*
 212 *to inject it. So I started injecting it. Before that I was smoking it. It was a control thing for*
 213 *him, being the control freak."* (Participant 4, age 36-40, SDS 10)

214

215 *"If I ever get in a co-dependant relationship or a violent relationship it was usually based*
 216 *around using of ice. If they went to jail I stopped using"* (Participant 6, age 41-45, SDS 9)

217

218 Partners were also described as key to the participant's initial use of MA.

219

220 *"I never used to like the ice...it was only through a boyfriend I was with, but before that the*
 221 *thought of it - I hated it. It was first it was around having sex, get on the high before having*
 222 *sex or while having sex. I did it at the beginning to please my partner – I never really did it for*
 223 *me."* (Participant 4, age 36-40, SDS 10)

224

225 Institutionalised stigma

226

227 Participants identified situations in which they faced institutional prejudice and stigma,
228 particularly within the healthcare and criminal justice systems.

229

230 *“With police you know, I always have issues with them you know because of my drug history.*
231 *Once they know you’re a drug user they treat you different...To them I think you know you’re*
232 *a piece of shit...so they talk down to you...Even in domestic violence situations where I've*
233 *been badly bashed or whatever they still treat you the same.”* (Participant 4, age 36-40, SDS
234 10)

235

236 This extended into healthcare interactions, and participants reported that this impacted on
237 their willingness to ask or receive help.

238

239 *“I don't know if I was paranoid but yeah with some doctors I felt once they realised you're a*
240 *sex worker or a drug user their whole persona changes.”* (Participant 4, age 36-40, SDS 10)

241

242 *“I had to wait two hours... and it wasn't until I started crying and going just because you*
243 *couldn't... you know no one can see my symptoms.”* (Participant 8, age 41-45, SDS 3)

244

245 Participants identified how feelings of shame affected their capacity to seek help.

246

247 *“I feel a bit shame about what I've been through and I didn't wanna talk about it cos I didn't*
 248 *know how to express it. Now that I'm over it and I've realised what I've been through I can*
 249 *talk and express it.”* (Participant 2, age 25-30, SDS 11)

250

251 Even when seeking help, participants emphasised the challenge in communicating their
 252 distress to healthcare workers.

253

254 *“No one knew what I was going through because they hadn't been through it, or they never*
 255 *knew anyone in that situation before...I wasn't speaking the right words.”* (Participant 2, age
 256 25-30, SDS 11)

257

258 Health service delivery preferences

259

260 We identified three key themes around participant's preferences for health service delivery:
 261 trusted continuous care; care that's integrated with other services; and is free of judgment.

262

263 Trusted continuous care

264

265 Participants valued continuity of care from healthcare professionals that knew their
 266 individual history and they had built a therapeutic relationship with over an extended period
 267 of time. It gave participants a sense of trust and belonging.

268

269 *"Sometimes I guess I feel shy around people I don't know. The last couple of times I've been*
 270 *shifted around to a different person and I'm not gonna start telling them my dark secrets."*

271 (Participant 7, age 41-45, SDS 11)

272

273 *"I have...a problem with feeling comfortable with certain people and trust issues. If I don't*
 274 *feel comfortable or if I don't like you I won't be sitting there. It's taken weeks, months if not*
 275 *years before I even sit down and have a conversation with you."* (Participant 4, age 36-40,

276 SDS 10)

277

278 Integrated with other services

279

280 Participants valued services who had an integrated approach to medical care, psychological
 281 and social service support.

282

283 *"It's the place that I'll go to for everything...they're the best people...I see my psychiatrist*
 284 *there, my doctors there, and my counsellor...my folder's about that thick [laughs]."*

285 (Participant 1, age >50, SDS 5)

286

287 Culturally appropriate services were also valued.

288

289 *"[Aboriginal Health Worker] gets what I like, what I don't like. She even knows the clothes I*
 290 *like to wear...Whenever I get any of the ladies that are downstairs, that are non-Indigenous,*
 291 *they always come out with old people clothes."* (Participant 11, age 46-50, SDS 9).

292

293 Non-judgmental

294

295 Participants feared experiencing discrimination due to their drug use when seeking help
296 from health professionals, and described how non-judgemental care improved their
297 interactions with health services.

298

299 *"I like it because they don't discriminate ... that they really make me feel I'm not different. I*
300 *can just talk to them just to let it out and I never snap. [At other places] it was like guilty I*
301 *had to prove myself innocent."* (Participant 1, age >50, SDS 5)

302

303 Discussion

304

305 In this study, we explored the perspectives of a sample of 11 diverse women who regularly
306 use MA and their healthcare service delivery preferences. Findings point toward several
307 areas which might be addressed to promote earlier specialist treatment-seeking by women
308 who use MA.

309

310 Working with stigma

311

312 Effective assessment of substance use issues is key to facilitating earlier recognition of
313 substance use disorders, and engagement with specialist treatment. The self-identification
314 of problematic use was complicated for participants in the study by feelings of shame and
315 the fear of experiencing discrimination. Women who use drugs may be more susceptible to

feeling stigmatised than men (Meyers et al., 2021) , and are reported to be more likely to experience stigma as a barrier to treatment (Green, 2006). Countering stigma is a key competency for professionals working with this group (Bielenberg, Swisher, Lembke, & Haug, 2021). Green (2006) found that women were most likely to seek help for substance use in primary healthcare and mental healthcare, highlighting the need for effective engagement in for both AOD and non-AOD services. It also suggests a role for specialist MaUD treatment programs to work with and upskill healthcare professionals in non-specialist AOD and other healthcare settings

It is also notable that participants readily identified benefits to their use of MA, such as increased productivity and sociability. People may not readily identify their ambivalence around reducing or ceasing MA use in healthcare settings, given the stigma of drug-related pleasure (Pienaar & Dilkes-Frayne, 2017). Healthcare professionals should recognise there are different stages in readiness to addressing drug use, and have a number of strategies to engage accordingly. Motivational interviewing, for instance, takes account of readiness to change, and can be effective after just one session when delivered by healthcare professionals in non-AOD settings (VanBuskirk & Wetherell, 2014).

Working with social networks

A prominent theme among study participants was the interaction between social relationships, their experience of MA use, and treatment seeking. Intimate relationships were implicated in onset and continuation of MA use for some, and relationships involving trauma and violence were common. Women with substance use disorders have been

reported as having higher rates of trauma histories than men (Simpson et al., 2016), with up to 80% of women who seek treatment for substance use disorder estimated to have lifetime histories of sexual and/or physical trauma (López-Castro, Hu, Papini, Ruglass, & Hien, 2015). This underscores the need for trauma and violence-informed care in all settings (Wathen, MacGregor, & Beyrem, 2021), with health professionals trained in the empathetic eliciting and recognition of intimate partner violence, robust systems of referral, and an understanding of the impact of trauma on health and help-seeking.

A number of the participants had experienced engagement with child protection services, consistent with substance use being recognised as a predictor of children being taken into care at birth (Wall-Wieler, Roos, Brownell, Nickel, & Chateau, 2018). An Australian study of a sample of MA smokers found that in addition to experiences of poverty and homelessness, accessing treatment was also associated with an increased likelihood of child-removal for women (Ward et al., 2021). The risk of child removal in addition to stigmatisation and high rates of disadvantage and trauma for this population (O'Connor et al., 2020; O'Connor, Harris, Hamilton, Fisher, & Sachmann, 2021) underline the need for careful assessment and adequate support for this population when engaging with services.

Importantly, relationships were regarded as resource and a driver for treatment seeking and utilisation by participants. This mirrors the growing recognition of the role of significant others (Ariss & Fairbairn, 2020) and social networks as a form of recovery capital (Best, Vanderplasschen, & Nisic, 2020; Collinson & Hall, 2021), and the inclusion of family and friends in treatment planning presents an opportunity to enhance outcomes in MaUD

treatment. Further research is required to build the evidence base for family and social network inclusive practices in MaUD treatment.

Countering power imbalances

Participants reported that experiences of stigma in interactions with healthcare and other institutional settings were common. This led to caution around disclosing their MA use in case it led to discriminatory attitudes or behaviours towards them when they were especially vulnerable, and underpins the value participants held for trusted relationships built over time with individual professionals in those institutions. Hospitals and other healthcare settings can be experienced as unsafe spaces by people who use drugs (McNeil, Small, Wood, & Kerr, 2014; Pauly, McCall, Browne, Parker, & Mollison, 2015). The inclusion of workers with lived experience in healthcare teams can be an effective strategy in reducing fear of discrimination and empowering clients (Olding, Cook, Austin, & Boyd, 2022). People may feel also more comfortable receiving healthcare outside of institutional settings, and so the delivery of specialist MaUD treatment through outreach and community partnerships, and with technological innovations such as telehealth, may also be of value in addressing these provider-client power imbalances.

Integrated and structurally competent service delivery

Participants in the study had needs across multiple domains, encompassing physical and mental health needs, income support, social support and justice involvement. This need for

integrated care to support the whole of a person's health needs through effective working across healthcare and other services has also been highlighted by other studies with people with substance use disorders (Petzold et al., 2021; Savic, Best, Manning, & Lubman, 2017).

The participants' accounts of disadvantage are also better understood as resilience in the face of structural vulnerability (Bourgois, Holmes, Sue, & Quesada, 2017), rather than behaviours or social risk factors. Such an understanding focuses on the ways in which social structures and power relationships make specific groups more or less likely to develop a substance use disorder, which is then compounded by inequities in access to healthcare treatment. As McKenna notes, poor and minority women who use drugs exist in risk environments characterised by multiple levels of structural, physical and symbolic violence (McKenna, 2014). This vulnerability is reinforced by stigmatizing drug policies, laws and media portrayals (McKenna, 2014). The multiple axes of structural vulnerability recounted by the participants in this study, not just gender, but also race, and poverty, underscore the need an intersectional approach to planning MaUD treatment services. structurally competent healthcare (Metzl & Hansen, 2014) seeks to produce workers and systems who recognise the effects of structural disadvantages on health and develop responses that prevent further harms. It is especially relevant in addressing the challenges to health equity that arise from systemic discrimination for people who use drugs (McNeil, Kerr, Pauly, Wood, & Small, 2016; Treloar et al., 2021), as well as inequities arising due to gender (Mackenzie, Gannon, Stanley, Cosgrove, & Feder, 2019; Preis, Garry, Herrera, Garretto, & Lobel, 2020).

Limitations

Our study is subject to a number of limitations. Firstly, the size and source of our sample means that the study should not be taken as a representative sample of women who use MA. For instance, the sample was drawn from those already accessing public health services, so may have missed more marginalised women. Conversely, those accessing

privately funded services may also have been missed. We also did not explicitly seek individuals who identified as transgender or gender diverse. This necessarily limits the generalisability of this study.

Conclusion

This study explored the perspectives of a diverse group of women on their MA use and preferences for healthcare. Findings show a complex interaction between the management of identity, self-stigma and the fear of discrimination and showed personal relationships as being both a challenge and a resource. Healthcare institutions were not seen as safe spaces, with integration and continuity of care delivered by non-judgemental staff valued by the participants, and the need for trauma and violence informed care in all settings was clear. Findings may also have relevance for healthcare interventions for a range of other substance use disorders. Future research on effective anti-stigma interventions for healthcare professionals, family inclusive practice, and structurally competent care will be of value in providing better access to MaUD treatment services for women.

Acknowledgements

The authors would like to acknowledge and pay their respects to the custodians of the land where the project was undertaken, the Gadigal people of the Eora Nation. They also offer their sincere gratitude to the women who participated in the study and shared their stories. Thanks to Leanne McQuiston for her support with transcription.

References

- Ariss, T., & Fairbairn, C. E. (2020). The effect of significant other involvement in treatment for substance use disorders: a meta-analysis. *Journal of Consulting and Clinical psychology, 88*(6), 526-540. doi:10.1037/ccp0000495
- Asharani, P. V., Hombali, A., Seow, E., Ong, W. J., Tan, J. H., & Subramaniam, M. (2020). Non-pharmacological interventions for methamphetamine use disorder: a systematic review. *Drug & Alcohol Dependence, 212*, 108060. doi:10.1016/j.drugalcdep.2020.108060
- Australian Institute of Health and Welfare. (2020). *Alcohol and other drug treatment services in Australia: 2018–19*. Canberra: AIHW
- Best, D., Vanderplasschen, W., & Nisic, M. (2020). Measuring capital in active addiction and recovery: the development of the strengths and barriers recovery scale (SABRS). *Substance abuse treatment, prevention and policy, 15*(1), 40-40. doi:10.1186/s13011-020-00281-7
- Bielenberg, J., Swisher, G., Lembke, A., & Haug, N. A. (2021). A systematic review of stigma interventions for providers who treat patients with substance use disorders. *Journal of Substance Abuse Treatment, 131*, 108486. doi:10.1016/j.jsat.2021.108486
- Bourgois, P., Holmes, S. M., Sue, K., & Quesada, J. (2017). Structural vulnerability: operationalizing the concept to address health disparities in clinical care. *Academic Medicine, 92*(3), 299-307. doi:10.1097/ACM.0000000000001294
- Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. *Qualitative Research in Psychology, 3*(2), 77-101. doi:10.1191/1478088706qp063oa
- Brecht, M.-L., Lovinger, K., Herbeck, D. M., & Urada, D. (2013). Patterns of treatment utilization and methamphetamine use during first 10 years after methamphetamine initiation. *Journal of Substance Abuse Treatment, 44*(5), 548-556. doi:10.1016/j.jsat.2012.12.006
- Brener, L., Lea, T., Rance, J., Wilson, H., Bryant, J., & Ezard, N. (2018). Providing a model of health care service to stimulant users in Sydney. *Drugs: Education, Prevention and Policy, 25*(2), 130-137. doi:10.1080/09687637.2016.1221061
- Broom, A., Hand, K., & Tovey, P. (2009). The role of gender, environment and Individual biography in shaping qualitative interview data. *International Journal of Social Research Methodology, 12*(1), 51-65. doi:10.1080/13645570701606028
- Chomchai, C., & Chomchai, S. (2015). Global patterns of methamphetamine use. *Current Opinion in Psychiatry, 28*(4), 269-274. doi:10.1097/ycp.0000000000000168

- 468 Collinson, B., & Hall, L. (2021). The role of social mechanisms of change in women's
469 addiction recovery trajectories. *Drugs: Education, Prevention and Policy*, 28(5), 426-
470 436. doi:10.1080/09687637.2021.1929077
- 471 Cumming, C., Troeung, L., Young, J. T., Kelty, E., & Preen, D. B. (2016). Barriers to accessing
472 methamphetamine treatment: A systematic review and meta-analysis. *Drug &*
473 *Alcohol Dependence*, 168, 263-273. doi:10.1016/j.drugalcdep.2016.10.001
- 474 Degenhardt, L., Sara, G., McKetin, R., Roxburgh, A., Dobbins, T., Farrell, M., . . . Hall, W. D.
475 (2017). Crystalline methamphetamine use and methamphetamine-related harms in
476 Australia. *Drug & Alcohol Review*, 36(2), 160-170. doi:10.1111/dar.12426
- 477 Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., . . .
478 McKetin, R. (2019). Responding to global stimulant use: challenges and
479 opportunities. *The Lancet*, 394(10209), 1652-1667. doi:10.1016/S0140-
480 6736(19)32230-5
- 481 Frydenberg, E. (2014). Coping research: Historical background, links with emotion, and new
482 research directions on adaptive processes. *Australian Journal of Psychology*, 66(2),
483 82-92. doi:10.1111/ajpy.12051
- 484 Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The
485 Severity of Dependence Scale (SDS): psychometric properties of the SDS in English
486 and Australian samples of heroin, cocaine and amphetamine users. *Addiction*, 90(5),
487 607-614. doi:10.1046/j.1360-0443.1995.9056072.x
- 488 Green, C. A. (2006). Gender and use of substance abuse treatment services. *Alcohol*
489 *Research & Health*, 29(1),55-62
- 490 Hser, Y.-I., Evans, E., & Huang, Y.-C. (2005). Treatment outcomes among women and men
491 methamphetamine abusers in California. *Journal of Substance Abuse Treatment*,
492 28(1), 77-85. doi:10.1016/j.jsat.2004.10.009
- 493 Keane, H. (2017). Female vulnerability and susceptible brains: Gendered discourses of
494 addiction. *The Social History of Alcohol and Drugs*, 31, 126-139.
495 doi:10.1086/shad31010126
- 496 Kenny, P., Harney, A., Lee, N. K., & Pennay, A. (2011). Treatment utilization and barriers to
497 treatment: results of a survey of dependent methamphetamine users. *Subst Abuse*
498 *Treat Prev Policy*, 6, 3. doi:10.1186/1747-597x-6-3
- 499 Lee, N., Harney, A., & Pennay, A. (2012). Examining the temporal relationship between
500 methamphetamine use and mental health comorbidity. *Advances in Dual Diagnosis*,
501 5(1), 23-31. doi:10.1108/17570971211225145
- 502 López-Castro, T., Hu, M.-C., Papini, S., Ruglass, L. M., & Hien, D. A. (2015). Pathways to
503 change: Use trajectories following trauma-informed treatment of women with co-
504 occurring post-traumatic stress disorder and substance use disorders. *Drug and*
505 *Alcohol Review*, 34(3), 242-251. doi:https://doi.org/10.1111/dar.12230

- 506 Mackenzie, M., Gannon, M., Stanley, N., Cosgrove, K., & Feder, G. (2019). 'You certainly
507 don't go back to the doctor once you've been told, "I'll never understand women like
508 you."' Seeking candidacy and structural competency in the dynamics of domestic
509 abuse disclosure. *Sociology of Health & Illness*, 41(6), 1159-1174. doi:10.1111/1467-
510 9566.12893
- 511 Man, N., Sisson, S. A., McKetin, R., Chrzanowska, A., Bruno, R., Dietze, P. M., . . . Peacock, A.
512 (2022). Trends in methamphetamine use, markets and harms in Australia, 2003–
513 2019. *Drug & Alcohol Review*, 41(5), 1041-1052.
514 doi:<https://doi.org/10.1111/dar.13468>
- 515 Martin, F. S., & Aston, S. (2014). A "Special Population" with "Unique Treatment Needs":
516 Dominant Representations of "Women's Substance Abuse" and Their Effects.
517 *Contemporary Drug Problems*, 41(3), 335-360. doi:10.1177/009145091404100304
- 518 McKenna, S. A. (2014). Navigating the Risk Environment: Structural Vulnerability, Sex, and
519 Reciprocity Among Women Who Use Meth. *International Journal of Drug Policy*
520 25(1), 112-115. doi:10.1016/j.drugpo.2013.09.006
- 521 McKetin, R., Dunlop, A. J., Holland, R. M., Sutherland, R. A., Baker, A. L., Salmon, A. M., &
522 Hudson, S. L. (2013). Treatment outcomes for methamphetamine users receiving
523 outpatient counselling from the Stimulant Treatment Program in Australia. *Drug &*
524 *Alcohol Review*, 32(1), 80-87. doi:10.1111/j.1465-3362.2012.00471.x
- 525 McKetin, R., & Kelly, E. (2007). Socio-demographic factors associated with
526 methamphetamine treatment contact among dependent methamphetamine users
527 in Sydney, Australia. *Drug & Alcohol Review*, 26(2), 161-168.
- 528 McNeil, R., Kerr, T., Pauly, B., Wood, E., & Small, W. (2016). Advancing patient-centered care
529 for structurally vulnerable drug-using populations: a qualitative study of the
530 perspectives of people who use drugs regarding the potential integration of harm
531 reduction interventions into hospitals. *Addiction*, 111(4), 685-694.
532 doi:10.1111/add.13214
- 533 McNeil, R., Small, W., Wood, E., & Kerr, T. (2014). Hospitals as a 'risk environment': An
534 ethno-epidemiological study of voluntary and involuntary discharge from hospital
535 against medical advice among people who inject drugs. *Social Science & Medicine*,
536 105, 59-66. doi: 10.1016/j.socscimed.2014.01.010
- 537 Metzl, J. M., & Hansen, H. (2014). Structural competency: Theorizing a new medical
538 engagement with stigma and inequality. *Social Science & Medicine*, 103, 126-133.
539 doi: 10.1016/j.socscimed.2013.06.032
- 540 Meyers, S. A., Earnshaw, V. A., D'Ambrosio, B., Courchesne, N., Werb, D., & Smith, L. R.
541 (2021). The intersection of gender and drug use-related stigma: A mixed methods
542 systematic review and synthesis of the literature. *Drug and Alcohol Dependence*,
543 223, 108706-108706. doi:10.1016/j.drugalcdep.2021.108706

- 544 O'Connor, A., Harris, E., Seeber, C., Hamilton, D., Fisher, C., & Sachmann, M. (2020).
545 Methamphetamine use in pregnancy, child protection, and removal of infants:
546 Tertiary centre experience from Western Australia. *Midwifery*, 83, 102641-102641.
547 doi:10.1016/j.midw.2020.102641
- 548 O'Connor, A., Harris, E., Hamilton, D., Fisher, C., & Sachmann, M. (2021). The experiences of
549 pregnant women attending a specialist service and using methamphetamine.
550 *Women & Birth*, 34(2), 170-179. doi:10.1016/j.wombi.2020.01.011
- 551 Olding, M., Cook, A., Austin, T., & Boyd, J. (2022). "They went down that road, and they get
552 it": A qualitative study of peer support worker roles within perinatal substance use
553 programs. *Journal of Substance Abuse Treatment*, 132, 108578.
554 doi:/10.1016/j.jsat.2021.108578
- 555 Pauly, B., McCall, J., Browne, A. J., Parker, J., & Mollison, A. (2015). Toward cultural safety:
556 Nurse and patient Perceptions of illicit substance use in a hospitalized setting.
557 *Advances in Nursing Science*, 38(2), 121-135. doi:10.1097/ans.0000000000000070
- 558 Petzold, J., Spreer, M., Krüger, M., Sauer, C., Kirchner, T., Hahn, S., . . . Pilhatsch, M. (2021).
559 Integrated care for pregnant women and parents with methamphetamine-related
560 mental disorders. *Frontiers in Psychiatry*, 12, 762041-762041.
561 doi:10.3389/fpsyt.2021.762041
- 562 Pienaar, K., & Dilkes-Frayne, E. (2017). Telling different stories, making new realities: The
563 ontological politics of 'addiction' biographies. *International Journal of Drug Policy*,
564 44, 145-154. doi:10.1016/j.drugpo.2017.05.011
- 565 Preis, H., Garry, D. J., Herrera, K., Garretto, D. J., & Lobel, M. (2020). Contextualizing life
566 context: Discrimination, structural competency, and evaluation in the treatment of
567 pregnant women with opioid use disorder. *Women's Reproductive Health*, 7(3), 185-
568 189. doi:10.1080/23293691.2020.1780394
- 569 Quinn, B., Stooze, M., Papanastasiou, C., & Dietze, P. (2013). An exploration of self-
570 perceived non-problematic use as a barrier to professional support for
571 methamphetamine users. *International Journal of Drug Policy*, 24(6), 619-623.
572 doi:10.1016/j.drugpo.2013.05.015
- 573 Rapp, R. C., Xu, J., Carr, C. A., Lane, D. T., Wang, J., & Carlson, R. (2006). Treatment barriers
574 identified by substance abusers assessed at a centralized intake unit. *Journal of*
575 *Substance Abuse Treatment*, 30(3), 227-235. doi:10.1016/j.jsat.2006.01.002
- 576 Roche, A., McEntee, A., Fischer, J., & Kostadinov, V. (2015). *Methamphetamine use in*
577 *Australia*. Adelaide, South Australia: National Centre for Education and Training on
578 Addiction (NCETA), Flinders University.
- 579 Savic, M., Best, D., Manning, V., & Lubman, D. I. (2017). Strategies to facilitate integrated
580 care for people with alcohol and other drug problems: a systematic review.
581 *Substance Abuse Treatment, Prevention and Policy*, 12(1), 19-19.
582 doi:10.1186/s13011-017-0104-7

583 Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020). Pharmacological treatment of
584 methamphetamine/amphetamine dependence: A systematic review. *CNS Drugs*,
585 34(4), 337-365. doi:10.1007/s40263-020-00711-x

586 Simpson, J. L., Grant, K. M., Daly, P. M., Kelley, S. G., Carlo, G., & Bevens, R. A. (2016).
587 Psychological burden and gender differences in methamphetamine-dependent
588 individuals in treatment. *Journal of Psychoactive Drugs*, 48(4), 261-269.
589 doi:10.1080/02791072.2016.1213470

590 Treloar, C., Schroeder, S., Lafferty, L., Marshall, A., Drysdale, K., Higgs, P., . . . Dietze, P.
591 (2021). Structural competency in the post-prison period for people who inject drugs:
592 A qualitative case study. *International Journal of Drug Policy*, 95, 103261.
593 doi:https://doi.org/10.1016/j.drugpo.2021.103261

594 VanBuskirk, K. A., & Wetherell, J. L. (2014). Motivational interviewing with primary care
595 populations: a systematic review and meta-analysis. *Journal of Behavioral Medicine*,
596 37(4), 768-780. doi:10.1007/s10865-013-9527-4

597 Wall-Wieler, E., Roos, L. L., Brownell, M., Nickel, N. C., & Chateau, D. (2018). Predictors of
598 having a first child taken into care at birth: A population-based retrospective cohort
599 study. *Child Abuse & Neglect*, 76, 1-9. doi:10.1016/j.chiabu.2017.09.033

600 Ward, B., Kippen, R., Reupert, A., Maybery, D., Agius, P. A., Quinn, B., . . . Dietze, P. M.
601 (2021). Parent and child co-resident status among an Australian community-based
602 sample of methamphetamine smokers. *Drug & Alcohol Review*, 40(7), 1275-1280.
603 doi:10.1111/dar.13155

604 Wathen, C. N., MacGregor, J. C. D., & Beyrem, S. (2021). Impacts of trauma- and violence-
605 informed care education: A mixed method follow-up evaluation with health & social
606 service professionals. *Public Health Nursing*, 38(4), 645-654. doi:10.1111/phn.12883

607

608

609

610

611

612

613

614

Table 1: Participant characteristics

	Number (%)
Demographic	
Total sample	11
Gender (identified as woman)	11 (100)
Age range in years	
25-35	2 (9)
36-40	2 (18)
41-45	4 (36)
46+	3 (27)
Aboriginal/Torres Strait Islander	3 (27)
Sexual Orientation	
Heterosexual	7 (63)
Bisexual/Queer	4 (37)
Relationship Status	
In a relationship	6 (55)
Experiencing Homelessness	5 (45)
Mode of MA use	
IV	11 (100)
Inhalation	2 (also smoked)
Frequency of use (last 30 days)	
>2 times per week	11 (100)
Daily	7 (63)
Duration of frequent use	
<5 years	5 (45)
5-10 years	4 (37)
20 years +	2 (18)
Dependence on MA	
SDS >= 4	8 (72)
Self-described dependence	7 (63)
Reported Use/Dependence on Other Drugs	
Opiates	10 (90) / 7 (63)
Alcohol	11 (100) / 1 (1)
Cigarettes	10 (90) / 7 (63)
GHB/GBL	8 (72) / 0 (0)
Cannabis	11 (100) / 3 (27)
BZD	10 (90) / 2 (18)
Self-reported severe harms related to MA	
Physical*	10 (90)
Mental**	6 (55)
Social***	11 (100)

*Heart attack, cardiac stents, chest pain, bacterial endocarditis, oral decay, abscesses, staphylococcus skin infections, hepatitis, persistent cough

**Psychosis, severe mood swings, depression, anxiety, paranoia, hallucinations

***Intimate partner violence, domestic violence, violence, imprisonment, loss of custody of children, debt, gambling, poverty, homelessness